Equibles does not estimate personal net worth.
Get an email with a short summary when Neurocrine Biosciences Inc publishes a filing, an earnings call transcript or a press release.
Get NBIX alertsKyle Gano has spoken on 9 earnings calls across 1 company, most recently for Neurocrine Biosciences Inc on July 30, 2026. Neurocrine Biosciences Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Neurocrine Biosciences Inc includes Kevin Gorman (CEO and Board Member), Kyle Gano, Ph.D. (CEO and Board Member), Kyle W. Gano (CEO and Board Member) and 7 others.
“Neurocrin's second quarter performance demonstrates the power of a diversified growth strategy built to compound over time.”
“Over the past several years, we've articulated a clear vision to become a leading biopharmaceutical company driven by growing and diversifying our revenue base while advancing and expanding our pipeline.”
“A hallmark of a healthy company is the strength of the foundation beneath it. As Neurocrin enters 2026, our foundation is stronger than at any point in our more than 30-year history, and it continues to strengthen.”
“Our third quarter results reflect Neurocrine's exceptional execution and the strength of our enterprise-wide momentum as we continue to deliver across our commercial, clinical and operational objectives.”
“Neurocrine has never been in a stronger position as we maintain an enterprise-wide focus on execution and evolution. Even with external factors continuing to create market volatility, we remain focused on controlling what we can, executing with discipline to meaningfully deliver for both patients and shareholders.”
Source not stated
Drug Manufacturers - Specialty & Generic · Healthcare
